Troutman Pepper Hamilton Sanders LLP advised Inhibikase Therapeutics, Inc. on the deal. Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company developing therapeutics for Parkinson’s Disease…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
